Eli Lilly shows obesity drug Zepbound can treat sleep apnea too

The latest stories trending on MedCity News.

Editor's Pick

Top Story Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea. Lilly is now preparing regulatory submissions to add this indication to the drug's label. 6 Women's Health Startups You Should Get to Know Women's health is the theme for the MedCity INVEST healthcare startup pitch contest track focused on Consumer/ Employer healthcare and these health tech companies (GoNo Food Finder, Coologics, Estringenex Therapeutics, Mother's Milk Is Best's, NOMA AI, and Marma) will take part in the MedCity INVEST Pitch Perfect contest May 21-22 in Chicago. Hurry, space is limited. Get your ticket today and get ready to create new opportunities. Register today!

Featured News

What Does the FTC's $7M Fine Against Cerebral Mean for the Industry? This week, the FTC ordered Cerebral to pay a $7 million fine, accusing the company of mishandling users' sensitive health data and misleading consumers about cancellation policies. Experts agree that other virtual healthcare providers need to work on their legal and compliance strategies in order to avoid a similar fate.

Resources

MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Brian Anderson, CEO of the Coalition for Health AI In this month's episode, Senior Reporter Katie Adams discussed some executive hires, promotions and departures that recently occurred in the healthcare world, as well as layoffs affecting the industry. We also hear from Brian Anderson, who recently became CEO of the Coalition for Health AI (CHAI). Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe